Revenue Summary of Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc.'s latest annual revenue in 2023 was 8.94 Million USD , down -39.16% from previous year.
Lineage Cell Therapeutics, Inc.'s latest quarterly revenue in 2024 Q2 was 1.4 Million USD , down -2.49% from previous quarter.
Lineage Cell Therapeutics, Inc. reported a annual revenue of 14.7 Million USD in annual revenue 2022, up 277.39% from previous year.
Lineage Cell Therapeutics, Inc. reported a annual revenue of 3.89 Million USD in annual revenue 2021, up 404.01% from previous year.
Lineage Cell Therapeutics, Inc. reported a quarterly revenue of 1.44 Million USD for 2024 Q1, down -30.84% from previous quarter.
Lineage Cell Therapeutics, Inc. reported a quarterly revenue of 2.38 Million USD for 2023 Q1, up 24.6% from previous quarter.

Annual Revenue Chart of Lineage Cell Therapeutics, Inc. (2023 - 1992)

Historical Annual Revenue of Lineage Cell Therapeutics, Inc. (2023 - 1992)

Year	Revenue	Revenue Growth
2023	8.94 Million USD	-39.16%
2022	14.7 Million USD	277.39%
2021	3.89 Million USD	404.01%
2020	773 Thousand USD	-47.7%
2019	1.47 Million USD	4.38%
2018	1.41 Million USD	-20.98%
2017	1.79 Million USD	-20.43%
2016	2.25 Million USD	-11.13%
2015	2.53 Million USD	30.19%
2014	1.94 Million USD	-31.97%
2013	2.86 Million USD	69.0%
2012	1.69 Million USD	-61.13%
2011	4.35 Million USD	18.33%
2010	3.68 Million USD	91.17%
2009	1.92 Million USD	28.02%
2008	1.5 Million USD	43.75%
2007	1.04 Million USD	-9.97%
2006	1.16 Million USD	28.66%
2005	903.2 Thousand USD	31.21%
2004	688.37 Thousand USD	23.71%
2003	556.42 Thousand USD	43.77%
2002	387.02 Thousand USD	154.76%
2001	151.91 Thousand USD	189.41%
2000	52.49 Thousand USD	-94.94%
1999	1.03 Million USD	245.83%
1998	300 Thousand USD	200.0%
1997	100 Thousand USD	0.0%
1996	100 Thousand USD	0.0%
1995	100 Thousand USD	0.0%
1994	100 Thousand USD	0.0%
1993	100 Thousand USD	0.0%
1992	100 Thousand USD	0.0%

Year	Revenue	Revenue Growth
2024 Q2	1.4 Million USD	-2.49%
2024 Q1	1.44 Million USD	-30.84%
2023 Q1	2.38 Million USD	24.6%
2023 Q4	2.08 Million USD	67.58%
2023 Q2	3.22 Million USD	35.16%
2023 Q3	1.24 Million USD	-61.36%
2023 FY	8.94 Million USD	-39.16%
2022 FY	14.7 Million USD	277.39%
2022 Q3	2.99 Million USD	-34.15%
2022 Q4	1.91 Million USD	-36.12%
2022 Q1	5.23 Million USD	445.52%
2022 Q2	4.55 Million USD	-13.06%
2021 Q3	2.2 Million USD	399.32%
2021 FY	3.89 Million USD	404.01%
2021 Q4	960 Thousand USD	-56.4%
2021 Q1	293 Thousand USD	76.51%
2021 Q2	441 Thousand USD	50.51%
2020 Q3	342 Thousand USD	245.45%
2020 FY	773 Thousand USD	-47.7%
2020 Q1	166 Thousand USD	-80.05%
2020 Q4	166 Thousand USD	-51.46%
2020 Q2	99 Thousand USD	-40.36%
2019 Q1	179 Thousand USD	4.68%
2019 Q3	217 Thousand USD	-13.2%
2019 Q4	832 Thousand USD	283.41%
2019 FY	1.47 Million USD	4.38%
2019 Q2	250 Thousand USD	39.66%
2018 Q3	264 Thousand USD	-56.44%
2018 FY	1.41 Million USD	-20.98%
2018 Q1	375 Thousand USD	-34.09%
2018 Q4	171 Thousand USD	-35.23%
2018 Q2	606 Thousand USD	61.6%
2017 Q1	379 Thousand USD	-50.0%
2017 FY	1.79 Million USD	-20.43%
2017 Q4	569 Thousand USD	22.89%
2017 Q2	381 Thousand USD	0.53%
2017 Q3	463 Thousand USD	21.52%
2016 Q4	758 Thousand USD	94.36%
2016 Q1	586 Thousand USD	5.59%
2016 Q2	506 Thousand USD	-13.65%
2016 Q3	390 Thousand USD	-22.92%
2016 FY	2.25 Million USD	-11.13%
2015 Q1	565.61 Thousand USD	27.33%
2015 Q2	572 Thousand USD	1.13%
2015 Q4	555 Thousand USD	-33.93%
2015 FY	2.53 Million USD	30.19%
2015 Q3	840 Thousand USD	46.85%
2014 Q2	466.66 Thousand USD	-4.95%
2014 Q3	543.52 Thousand USD	16.47%
2014 Q4	444.2 Thousand USD	-18.27%
2014 Q1	490.97 Thousand USD	-61.05%
2014 FY	1.94 Million USD	-31.97%
2013 Q3	553.63 Thousand USD	5.89%
2013 Q2	522.84 Thousand USD	-0.25%
2013 Q1	524.14 Thousand USD	1.15%
2013 FY	2.86 Million USD	69.0%
2013 Q4	1.26 Million USD	127.66%
2012 Q2	1.03 Million USD	63.57%
2012 Q1	631.94 Thousand USD	-61.26%
2012 FY	1.69 Million USD	-61.13%
2012 Q3	1 Million USD	-2.91%
2012 Q4	518.16 Thousand USD	-48.37%
2011 Q3	1.14 Million USD	51.29%
2011 Q1	824.62 Thousand USD	-41.88%
2011 Q2	755.55 Thousand USD	-8.38%
2011 Q4	1.63 Million USD	42.7%
2011 FY	4.35 Million USD	18.33%
2010 Q3	815.28 Thousand USD	19.85%
2010 Q1	767.12 Thousand USD	2.37%
2010 FY	3.68 Million USD	91.17%
2010 Q2	680.27 Thousand USD	-11.32%
2010 Q4	1.41 Million USD	74.04%
2009 Q1	296.74 Thousand USD	4.02%
2009 Q2	432.09 Thousand USD	45.61%
2009 Q4	749.34 Thousand USD	67.64%
2009 Q3	446.99 Thousand USD	3.45%
2009 FY	1.92 Million USD	28.02%
2008 Q4	285.28 Thousand USD	-33.18%
2008 Q1	381.01 Thousand USD	6.27%
2008 Q3	426.93 Thousand USD	3.99%
2008 Q2	410.56 Thousand USD	7.75%
2008 FY	1.5 Million USD	43.75%
2007 Q4	358.52 Thousand USD	55.1%
2007 Q2	210.74 Thousand USD	-14.23%
2007 Q1	245.69 Thousand USD	-48.82%
2007 FY	1.04 Million USD	-9.97%
2007 Q3	231.15 Thousand USD	9.69%
2006 Q2	143.19 Thousand USD	-40.77%
2006 Q4	480.08 Thousand USD	61.65%
2006 Q3	296.99 Thousand USD	107.41%
2006 Q1	241.74 Thousand USD	8.69%
2006 FY	1.16 Million USD	28.66%
2005 FY	903.2 Thousand USD	31.21%
2005 Q1	191.08 Thousand USD	-0.46%
2005 Q2	249.27 Thousand USD	30.45%
2005 Q3	240.43 Thousand USD	-3.55%
2005 Q4	222.41 Thousand USD	-7.5%
2004 Q4	191.95 Thousand USD	12.66%
2004 Q1	130.7 Thousand USD	-48.27%
2004 Q2	195.33 Thousand USD	49.45%
2004 Q3	170.38 Thousand USD	-12.78%
2004 FY	688.37 Thousand USD	23.71%
2003 Q1	96.62 Thousand USD	-47.24%
2003 FY	556.42 Thousand USD	43.77%
2003 Q3	109.87 Thousand USD	12.92%
2003 Q2	97.29 Thousand USD	0.7%
2003 Q4	252.63 Thousand USD	129.94%
2002 Q3	85.84 Thousand USD	41.16%
2002 Q4	183.13 Thousand USD	113.33%
2002 FY	387.02 Thousand USD	154.76%
2002 Q1	57.23 Thousand USD	8.3%
2002 Q2	60.81 Thousand USD	6.25%
2001 Q2	29.95 Thousand USD	-8.37%
2001 Q1	32.69 Thousand USD	-37.71%
2001 Q3	36.41 Thousand USD	21.56%
2001 FY	151.91 Thousand USD	189.41%
2001 Q4	52.84 Thousand USD	45.12%
2000 Q3	1.00 USD	0.0%
2000 FY	52.49 Thousand USD	-94.94%
2000 Q1	1.00 USD	-100.0%
2000 Q2	1.00 USD	0.0%
2000 Q4	52.49 Thousand USD	5249000.0%
1999 Q2	600 Thousand USD	50.0%
1999 Q1	400 Thousand USD	0.0%
1999 FY	1.03 Million USD	245.83%
1999 Q4	37.5 Thousand USD	-62.5%
1999 Q3	100 Thousand USD	-83.33%
1998 Q1	100 Thousand USD	-80.0%
1998 FY	300 Thousand USD	200.0%
1998 Q3	100 Thousand USD	-75.0%
1998 Q2	400 Thousand USD	300.0%
1997 FY	100 Thousand USD	0.0%
1997 Q1	100 Thousand USD	0.0%
1997 Q4	500 Thousand USD	400.0%
1997 Q3	100 Thousand USD	0.0%
1997 Q2	- USD	-100.0%
1996 Q2	- USD	-100.0%
1996 Q3	100 Thousand USD	0.0%
1996 Q4	100 Thousand USD	0.0%
1996 FY	100 Thousand USD	0.0%
1996 Q1	100 Thousand USD	0.0%
1995 Q3	100 Thousand USD	0.0%
1995 Q4	100 Thousand USD	0.0%
1995 Q2	- USD	-100.0%
1995 Q1	100 Thousand USD	0.0%
1995 FY	100 Thousand USD	0.0%
1994 Q1	100 Thousand USD	0.0%
1994 FY	100 Thousand USD	0.0%
1994 Q3	100 Thousand USD	0.0%
1994 Q2	- USD	-100.0%
1994 Q4	100 Thousand USD	0.0%
1993 Q1	100 Thousand USD	0.0%
1993 Q3	100 Thousand USD	0.0%
1993 Q4	100 Thousand USD	0.0%
1993 FY	100 Thousand USD	0.0%
1993 Q2	- USD	-100.0%
1992 Q2	- USD	-100.0%
1992 FY	100 Thousand USD	0.0%
1992 Q4	100 Thousand USD	0.0%
1992 Q1	100 Thousand USD	0.0%
1992 Q3	100 Thousand USD	0.0%

Peer Revenue Comparison of Lineage Cell Therapeutics, Inc.

Name	Revenue	Revenue Difference
AIM ImmunoTech Inc.	202 Thousand USD	-4328.218%
Ampio Pharmaceuticals, Inc.	- USD	-Infinity%
Armata Pharmaceuticals, Inc.	4.52 Million USD	-97.505%
Actinium Pharmaceuticals, Inc.	81 Thousand USD	-10943.21%
Azitra, Inc.	686 Thousand USD	-1203.936%
Can-Fite BioPharma Ltd.	743 Thousand USD	-1103.903%
Chromocell Therapeutics Corporation	- USD	-Infinity%
Calidi Biotherapeutics, Inc.	- USD	-Infinity%
CEL-SCI Corporation	- USD	-Infinity%
iBio, Inc.	225 Thousand USD	-3875.556%
MAIA Biotechnology, Inc.	- USD	-Infinity%
Matinas BioPharma Holdings, Inc.	1.09 Million USD	-716.15%
Navidea Biopharmaceuticals, Inc.	65.65 Thousand USD	-13524.871%
NovaBay Pharmaceuticals, Inc.	14.72 Million USD	39.257%
NanoViricides, Inc.	- USD	-Infinity%
Oragenics, Inc.	37.65 Thousand USD	-23656.407%
BiomX Inc.	-357 Thousand USD	2605.602%
BiomX Inc.	-357 Thousand USD	2605.602%
Protalix BioTherapeutics, Inc.	65.49 Million USD	86.342%
Palatin Technologies, Inc.	4.49 Million USD	-99.216%
Scorpius Holdings, Inc.	6.99 Million USD	-27.88%

Global Stocks Search

Lineage Cell Therapeutics, Inc. (LCTX)

Revenue Summary of Lineage Cell Therapeutics, Inc.

Annual Revenue Chart of Lineage Cell Therapeutics, Inc. (2023 - 1992)

Historical Annual Revenue of Lineage Cell Therapeutics, Inc. (2023 - 1992)

Peer Revenue Comparison of Lineage Cell Therapeutics, Inc.